Figure 2.
Serum concentration-time profiles for crizanlizumab. Mean and median serum concentration-time profiles for the crizanlizumab 5.0 and 7.5 mg/kg dose groups at starting dose (A) and steady state (PAS2) (B).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.